Indian pharmaceutical manufacturer Divi’s Laboratories increased September-quarter consolidated net profit to 11.27 billion rupees, nearly 64% above the year-earlier figure. Operating revenue rose to 36.76 billion rupees. Profit also increased over the April–September half year, while foreign-exchange gains declined. Consolidated results and the company’s standalone accounts showed different profit totals.
Divi’s Laboratories, an Indian pharmaceutical manufacturer, reported consolidated net profit of 11.27 billion rupees for July–September, up from 6.89 billion rupees in the same quarter a year earlier. Its second-quarter fiscal 2027 results were announced on November 7. Quarterly total income rose from 28.60 billion rupees to 37.70 billion rupees. Profit before tax was 15.05 billion rupees, compared with 9.12 billion rupees a year earlier.[1], [2]
Operating revenue grows as currency gains decline
Operating revenue increased 35.4% to 36.76 billion rupees from 27.15 billion rupees. Consolidated foreign-exchange gains fell to 240 million rupees, against 630 million rupees in the comparative quarter. In the standalone accounts, which cover the company separately from the consolidated group, quarterly net profit rose from 6.96 billion rupees to 11.40 billion rupees. Standalone total income increased from 28.06 billion rupees to 37.35 billion rupees.[1]
Half-year earnings rise to 20.29 billion rupees
For April–September as a whole, consolidated net profit reached 20.29 billion rupees, compared with 12.34 billion rupees in the preceding year’s first half. Total income grew from 53.89 billion rupees to 69.07 billion rupees. First-half foreign-exchange gains decreased to 170 million rupees from 1.02 billion rupees. Standalone net profit for the six months was 20.31 billion rupees, while standalone total income amounted to 67.65 billion rupees.[1]
